Physician profile
Tanisha Mathur
NPI 1669634671
$2,108.99
in general payments reported to CMS, 2019-2025
11 companies · $558 in 2025
The $558 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $414 · 2021: $53.40 · 2022: $337 · 2023: $318 · 2024: $190 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.75 |
| Education | $104.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $466.67 | 2020-2025 | Evenity, Otezla, Prolia |
| Janssen Biotech, INC. | $319.88 | 2020-2023 | Tremfya |
| Ucb, INC. | $278.98 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $268.74 | 2019-2020 | |
| Abbvie INC. | $209.43 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $183.61 | 2019-2024 | |
| Genentech USA, INC. | $143.99 | 2019-2023 | Actemra |
| Astrazeneca Pharmaceuticals LP | $126.28 | 2022-2023 | Saphnelo |
| Ani Pharmaceuticals, INC. | $70.08 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $26.53 | 2022-2023 | Taltz |
| Celltrion USA INC. | $14.80 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanisha Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.